【摘要】 目的 观察醋酸甲羟孕酮、戊酸雌二醇治疗围绝经期综合征的效果及对雌激素水平、子宫内膜的影响，并评价其安全性。方法 回顾性分析2018年2月—2021年1月收治的围绝经期综合征79例的临床资料，按照治疗方式分为研究组41例和对照组38例，研究组给予戊酸雌二醇治疗，对照组给予醋酸甲羟孕酮治疗。比较2组临床疗效、雌激素水平、子宫内膜厚度及子宫体积，记录2组不良反应发生情况。结果 研究组总有效率高于对照组(P<0.05)。治疗后，2组雌二醇均较治疗前升高，卵泡刺激素和黄体生成素均较治疗前下降，且研究组优于对照组(P<0.05,P<0.01)。2组治疗后子宫内膜厚度均较治疗前增加(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论 围绝经期综合征患者予戊酸雌二醇治疗效果显著，可有效改善雌激素水平，且安全性较高。更多还原

【Abstract】 Objective To observe clinical efficacy of Medroxyprogesterone Acetate and Estradiol Valerate in treatment of patients with perimenopausal period syndrome and their effects on estrogen levels and endometrium, and to evaluate their safety. Methods Clinical data of 79 patients with perimenopausal period syndrome admitted between February 2018 and January 2021 was retrospectively analyzed, and the patients were divided into research group(n=41) and control group(n=38) according to therapeutic methods. Research group was treated with Estradiol Valerate, while control group was treated with Medroxyprogesterone Acetate. Clinical efficacy, estrogen level, endometrial thickness and uterine volume were compared, and incidence rates of adverse reactions were recorded in two groups. Results The total effective rate in research group was significantly higher than that in control group(P<0.05). After treatment, estradiol levels were significantly increased, follicle stimulating hormone and luteinizing hormone were significantly decreased than those before treatment in both groups, and the improved conditions in research group were more significant than those in control group(P<0.05, P<0.01). The endometrial thicknesses were significantly increased after treatment than those before treatment in both groups(P<0.05). There was no significant difference in incidence rate of adverse reactions between two groups(P>0.05). Conclusion Estradiol Valerate is more effective in treatment of patients with perimenopausal period syndrome, which may effectively improve estrogen level with good safety.更多还原